Video

Dr. Finn on Regorafenib for the Treatment of Patients With HCC

Author(s):

Richard S. Finn, MD

Richard Finn, assistant professor of Medicine at the Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology at UCLA Jonsson Comprehensive Cancer Center, discusses regorafenib (Stivarga) for the treatment of patients with hepatocelluar carcinoma (HCC).

Richard Finn, assistant professor of Medicine at the Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology at UCLA Jonsson Comprehensive Cancer Center, discusses regorafenib (Stivarga) for the treatment of patients with hepatocelluar carcinoma (HCC).

Related Videos
Vikas S. Ostwal, MD
Alexander I. Spira MD, PhD, FACP, FASCO
Adam DuVall, MD, MPH
Marco Davila, MD, PhD
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Michael Foote, MD, medical oncologist, assistant attending physician, Memorial Sloan Kettering Cancer Center
Marcella Ali Kaddoura, MD
Martin Dreyling, MD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Dr Shreenivas on the Association Between MUC1 and CLDN18 in GI Cancers
Related Content
Biliary Tract Cancer | © Sebastian Kaulitzki – stock.adobe.com
January 30th 2025

Nab-Paclitaxel Plus SOC Chemo Fails to Improve OS in Newly Diagnosed Advanced Biliary Tract Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, professor, medicine, Department of Biochemistry & Surgery, School of Medicine, University of Puerto Rico; affiliated investigator, Cancer Biology Division, University of Puerto Rico Comprehensive Cancer Center; director, Gastrointestinal Oncology Division, Oncologic Hospital Dr. Isaac González Martínez
January 29th 2025

FDA Approval of Tislelizumab Plus Chemo Offers a New Option in Advanced Gastric/GEJ Adenocarcinoma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Cancer | Image Credit: © catalin - stock.adobe.com
January 28th 2025

Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST

Gastrointestinal Cancer | Image Credit: © Crystal light – stock.adobe.com
January 27th 2025

Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium